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The intent of the present investigation is to develop and evaluate colon-specific coated tacrolimus solid 
dispersion pellet (SDP) that retards drug release in the stomach and small intestine but progressively 
releases in the colon. Tacrolimus-SDP was prepared by extrusion-spheronization technology and 
optimized by the micromeritic properties including flowability, friability, yields and dissolution rate. 
Subsequently, the pH-dependent layer (Eudragit L30D55) and time-dependent layer (Eudragit NE30D 
and L30D55) were coated on the SDP to form tacrolimus colon-specific pellets (CSP) using a fluidized 
bed coater. Under in vitro gradient pH environment, tacrolimus only released from CSP after changing 
pH to 6.8 and then quickly released in the phosphate buffer solution of pH 7.2. The Cmax of CSP was 
195.68 ± 3.14 ng/mL at Tmax 4.5 ± 0.24 h where as in case of SDP, the Cmax was 646.16 ± 8.15 ng/mL 
at Tmax 0.5 ± 0.03 h, indicating the ability of CSP targeted to colon. The highest area under the curve was 
achieved 2479.58 ± 183.33 ng·h/mL for SDP, which was 2.27-fold higher than tacrolimus suspension. 
However, the best biodistribution performance was achieved from CSP. In conclusion, SDP combining 
of pH- and time-dependent approaches was suitable for targeted delivery of tacrolimus to colon. 
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INTRODUCTION 
Ulcerative colitis (UC) is a type of inflammatory 
bowel disease related to the autoimmune system. The 
outbreak of acute UC has high mortality. The chronic 
UC generally deteriorates to colon cancer and eventually 
requires surgery (De Toni et al., 2015). Currently, 
the medicines of UC treatment include non-steroidal 
anti-inflammatory drugs, glucocorticoids, synthetic 
immunosuppressants and biologic agents (Park, Jeen, 
2015). Tacrolimus is a type of macrolide lactone with 
potent immunosuppressive activity, which is used for 
organ rejection prophylaxis in liver, kidney and small 
intestine transplantation (Fang, Ma, Gui, 2015). It 
potentially inhibits calcineurin phosphatase activity and 
prevents the generation of nuclear factor of activated 
T cells (NF-AT). NF-AT activates the cytokine genes 
related to interleukin (IL)-2, tumor necrosis factor-α and 
interferon-γ in T lymphocytes. The immunosuppressive 
effects of tacrolimus are partially mediated by inhibition of 
IL-2 secretion and decrease the number of IL-2 receptors 
for T lymphocyte activation (Navas-Lopez et al., 2014). 
The steroid resistance is related to the high levels of IL-2 
release and intrinsic properties of IL-2 receptor in steroid 
resistant lymphocytes (Ogata et al., 2006). Therefore, 
tacrolimus will induce steroid-refractory UC remission, 
and is considered as a second-line medicine in severe 
inflammatory bowel disease treatment (Miyoshi et al., 
2013). In a study conducted by Landy et al. (2013) a 
total of 25 patients with refractory UC had achieved and 
maintained clinical remission by oral tacrolimus in six 
months (Landy et al., 2013). 
Tacrolimus is a lipophilic molecule consisting of 
23-member macrolide lactone. Therefore, it is limited in 
oral absorption in gastrointestinal tract, which induces 
the variable and poor oral bioavailability (Tajdaran et al., 
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2015). In order to improve the bioavailability of tacrolimus, 
we had developed the tacrolimus-solid dispersion 
(SD) through solvent evaporation method in previous 
studies (Fang et al., 2016). SD generally provides a high 
maximum blood concentration (Cmax) in blood at early 
time period following oral administration, and the duration 
time of effective blood concentrations is relatively short 
(Tsunashima et al., 2016). On the other hand, tacrolimus 
in non-specific delivery systems is initially absorbed into 
blood circulation, and then is redistributed in colon tissue. 
This causes the effective drug concentration low and 
variable in colon tissue.
Oral colon-specific delivery systems (OCDDS) do 
not release drugs in stomach and small intestine after oral 
administration, but specifically release drug in cecum or 
colon part (Bansal et al., 2014). The commonly applied 
dosage forms of OCDDS are tablets, capsules, gels and 
pellets (Vemula, 2015a; Vemula, 2015b; Dodoo et al., 
2017; Bose, Elyagoby, Wong, 2014). The mechanisms 
of OCDDS mainly involve the following (Bansalet al., 
2014). (1) pH-dependent OCDDS, carrier material was 
disintegrated in the colon based on the specific gradient 
pH in the gastrointestinal tract (stomach pH: 0.9-1.5, 
small intestine pH: 6.0-6.8, colon pH: 6.5-7.8. (2) Time-
dependent OCDDS, carrier material was disintegrated in 
the colon based on constant transit time of carrier in the 
stomach and small intestine, generally arrived to the colon 
part after 4-5 h upon oral administration. (3) Microbial-
dependent OCDDS, carrier materials were degraded by 
the specific enzymes secreted by colonic bacteria in the 
colon part. Among these approaches, microbial-dependent 
OCDDS were limited on the choice of specific carrier 
materials (Xu et al., 2014). The pH-dependent OCDDS 
approach is simple for operation, but there some researches 
prove that infeasible by using only one strategy as OCDDS 
in different physiological and pathological conditions for 
colon delivery. Therefore, the pH-dependent OCDDS was 
assessed in combination with time-dependent OCDDS 
to ensure drug release site accurately under different 
physiological conditions (Vemula, Veerareddy, Devadasu, 
2015; Veerareddy, Vemula, 2012). For example, Park et al., 
reported that an enteric coated multiple-unit tablet system 
of bisacodyl consisting of Eudragit S/L-based pH-
dependent and time-dependent controlled release polymer 
of Eudragit RS provided selective drug release in colon. 
The pharmacokinetic evaluation in rabbits suggested that 
drug absorption from the time- and pH-dependent tablet 
was effectively retarded in stomach and small intestinal 
with lowered systemic exposure compared to marked 
product of Dulcolax®, but profound drug liberation was 
achieved in colon part (Park et al., 2017). 
Cons ide r ing  the  d i sadvan tages  o f  t ab le t 
manufacturing, including capping, laminations, variations 
in weight and the processing cost, an attempt was 
made to develop tacrolimus SD-based controlled-
release pellets. Pellet is a kind of multiple-dose drug 
delivery system, which has the advantages of reducing 
gastrointestinal irritation, non-affecting dietary rhythms, 
nice reproducibility of pharmacokinetics, etc. Furthermore, 
pellets are spherical small-unit delivery systems with the 
diameter of 0.5-1.5 mm. The research indicated that 
small-unit delivery systems like pellets have a longer 
retention time compared to big-unit delivery systems 
in gastrointestinal tract (Dhandapani, 2005). To our 
knowledge, no reports have investigated the combination 
of OCDDS and SD formulations for tacrolimus. Therefore, 
the aim of this study was to design a novel double enteric 
coated pellet of tacrolimus for colon targeted delivery. 
We initially developed tacrolimus solid dispersion pellet 
(SDP) and then optimized the formulation consisting of 
Eudragit NE30D and Eudragit L30D55 as time-dependent 
layer, and Eudragit L30D55 as pH-dependent layer for 
the tacrolimus colon-specific pellet (CSP) to achieve 
OCDDS. Eudragit is a water-soluble coating material 
suitable for industrial production. At present, colon-
targeted drugs with Eudragit coating are available on the 
market. Marketed mesalazine-loaded pellet formulation 
of Salofalk® granule was targeted to colon site by pH- 
and time-dependent coating layer of Eudragit L100 and 
Eudragit NE (Schellekens et al., 2007). Furthermore, 
the oral bioavailability of tacrolimus incorporated into 
SDP and CSP were evaluated. The pharmacokinetics 
and biodistribution profiles of tacrolimus-SDP and -CSP 
were comparatively evaluated in rats using tacrolimus 
suspension as a reference. 
MATERIAL AND METHODS
Material
Tacrolimus was obtained from Meryer Chemical 
Technology Ltd (Shanghai, China). Eudragit NE30D and 
Eudragit L30D55 dispersions were donated by Evonik 
Corporation (Germany). Starch was obtained from 
Dongyuan Pharm Ltd (Liaoning, China). Microcrystalline 
cellulose (MCC), carboxymethyl cellulose sodium 
(CMC-Na),  poly vinyl pyrrolidone (PVP) K30, 
carboxymethyl starch sodium (CMS-Na), low-substituted 
hydroxypropyl cellulose (L-HPC), silica gel and talc were 
obtained from Anhui Sunhere Pharmaceutical Excipients 
Ltd (Huainan, China). Triethyl citrate was obtained from 
Aladdin Corporation (Shanghai, China). Methanol and 
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acetonitrile (HPLC gradient grade) were obtained from 
Merck (Shanghai, China), Ascomycin was donated by 
Shanghai Xuhui District Central Hospital. Purified water 
from a Milli-Q system (Millipore,Bedford, MA, USA) 
was used throughout the experiment. All other materials 
used were of standard pharmacopoeia grade or analytical 
reagent grade. 
Preparation of tacrolimus solid dispersion
We had successfully prepared tacrolimus-SD by 
the solvent evaporation method in previous research 
(Fang et al., 2016). The results of fourier transform 
infrared spectroscopy, differential scanning calorimetry, 
scanning electron microscopic pictures of SD powder 
indicated that tacrolimus existed in an amorphous state 
with hydroxypropyl methyl cellulose (HPMC) in SD, 
resulting in in vitro dissolution enhancement compared 
to the marketed tacrolimus powder (Fang et al., 2016). 
In brief, tacrolimus and HPMC were accurately weighed 
and tacrolimus was completely dissolved in the mixture 
solution containing ethanol and dichloromethane (1:1, 
v/v). Then, HPMC was swollen and added by the mixture 
solution. The mixed solvent was evaporated under a water 
bath at 50 °C and dried in a vacuum drying oven at 45 °C 
for 24 h. After drying, SD powders were pulverized and 
classified by a sieve of 180 μm.
Preparation and optimization of tacrolimus solid 
dispersion pellets 
Tacrolimus-SDP was prepared by an extrusion-
spheronization process. Tacrolimus-SD and all the 
excipients were firstly sieved through a 0.154 mm mesh. 
The powders were blended and wetted with 5% PVP K30 
by 30% ethanol until a homogeneous mass was obtained. 
Subsequently, the wet mass was extruded in an extruder 
(Enger E-50/ R-250, Chongqing Enger Graulating and 
Coating Technology Co., Ltd, China) using a 0.8 mm 
mesh. The extrudates were subsequently spheronized at 
500 rpm for 5 min (Enger E-50/R-250, Chongqing Enger 
Graulating and Coating Technology Co., Ltd, China) and 
dried in a vacuum oven at 50 °C for 24 h. 
Micromeritic properties of tacrolimus solid 
dispersion pellets 
Micromeritic properties of pellets were determined 
prior to the coating process for SDP formulation 
optimization. Flowability, friability and yield were 
evaluated in an uncoated SDP sample. 
Flowability was evaluated by angle of repose (φ). 
The pellets (5 g) were placed on a smooth and flat plate. 
One side of plate was lifted slowly. The angle of repose 
was formed by inclined surface and horizontal line when 
90% of pellets start rolling. 
Friability (F) was determined to ensure that the 
pellets could be coated without loss of weight. The less 
friability of pellets was contributed to further coating. This 
was measured by comparing the pellets weight before 
and after a fluidized test at 0.8 m3/min air flow rate for 10 
min in the fluidized bed device. The pellets (20 g) were 
accurately weighed before the test.
The obtained pellets were sieved by 700-880 μm 
screens. The yield (Y%) was obtained using the following 
equation. 
Flowability, friability and yield tests were 
implemented in triplicate for each pellet batch and the 
results were averaged.
Time- and pH-dependent layer coating of 
tacrolimus colon-specific pellets
The time-dependent layer coating solution was 
prepared by mixing talc (anti-coherent agent) and the 
water dispersions of Eudragit NE30D and Eudragit 
L30D55. The pH-dependent layer coating solution was 
prepared by mixing talc (anti-coherent agent), triethyl 
citrate (plasticizer) and the dispersion of Eudragit 
L30D55. The mixed suspension was stirred until a uniform 
suspension was obtained (about 80 rpm, 30 min). The final 
solid content was 15% in the suspension. The coating 
solutions were sieved by 0.45 mm mesh before use.
Tacrolimus-loaded pellets were coated with time- 
and pH-dependent layer using a fluidized bed coater 
with a bottom sprayer (MinLab XP, DIOSNA Co., Ltd, 
Germany). The pellets were fluidized and exposured on a 
hot air. The resulted coating solutions were layered onto 
the surface of pellets. The process parameters of fluidized 
bed coater were as follows: air flow speed of 1.3 m3/min; 
atomization pressure of 0.8 MPa; peristaltic pump speed 
of 10 Hz; nozzle diameter of 0.5 mm, inlet temperature 
of 26 °C (time-dependent layer) / 40 °C (pH-dependent 
layer). The coating solution was stirred constantly to 
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maintain a uniform state and prevent talc deposition in 
coating process. After coating, the coated-pellets were 
further fluidized for 3 min and subsequently dried in an 
oven for 12 h at 40 °C.
In vitro release kinetic studies 
All in vitro release tests were conducted with 
Chinese Pharmacopoeia (ChP) (Edition 2015) apparatus 
of intelligent dissolution instrument (RC1208D, TDTF 
Co., Ltd, Tianjin, China) at 37 °C. ChP paddles rotating 
at a speed of 75 rpm were used. Coated-pellets (5 mg 
tacrolimus) were soaked in 750 mL of HCl solution 
(0.1 mol/L) at pH 1.2 for 2 h, then switched to 900 mL of 
ChP phosphate buffer solution (PBS) at pH 6.8 and pH 
7.2 for the remaining 3 h and 7 h, respectively. At given 
time intervals of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 h, 
4 mL samples were withdrawn and filtered through a 
0.45 μm solvent resistant filter. The equal amount of 4 mL 
release medium was complemented. The in vitro release 
experiments were performed in triplicate.
The concentrations of tacrolimus in each filtered 
sample were determined by the HPLC system (Agilent 
1200 series HPLC system, G1312A Binary Pump, 
G1314B Variable Wavelength Detector, Agilent Co., Ltd, 
USA). The determination of tacrolimus was performed 
using a Kromasil100-5C18 column (250 mm × 4.6 mm, 
5 μm, Akzo Nobel Co., Ltd, Sweden) at a wavelength 
of 220 nm at 40 °C. The mobile phase consisted of 
acetonitrile-distilled water (70:30, v/v) operating at a flow 
rate of 1.0 mL/min. The injection volume of sample was 
20 μL. All experiments were performed in triplicate. 
The data obtained from the in vitro release studies 
were performed using DDsolver software following below 
equation (Zhang et al., 2010). The data of in vitro release 
were fitted to Zero order, First order, Weibull and Higuchi 
models to explore the pattern and the release mechanisms 
from the formulations. Koresmeyer–Peppas model was 
used to understand the mechanism of drug release from 
the formulations. The mean dissolution time (MDT) was 
calculated by the following equation (Veerareddy, Vemula, 
2012): 
where i is the dissolution sample number, n is the number 
of dissolution sample time, tmid is the time at the midpoint 
between i and i = 1, and ΔM is the amount of drug 
dissolved between i and i = 1.
T10% and T80% (time in hours to take 10% and 
80% drug release, respectively) were calculated to clarify 
the colon-specific release from CSP (Vemula, Veerareddy, 
2013). In the pair-wise approach, the similarity factor (f2) 
using the mean percentage cumulative released values 
was performed by using the following equation (Vemula, 
2015a):
where n is the number of time points, Rt and Tt are 
cumulative release of reference and test preparation at time 
point t, respectively. The value of f2 ranges between 0 and 
100. When the test and reference profiles are identical, the 
value of f2 approaches to 100, and as the value decreases, 
the dissimilarity between the profiles increases.
In vivo pharmacokinetic and biodistribution 
studies of tacrolimus colon-specific pellets
Animal experiments
Male Sprague-Dawley rats were provided by 
Experimental Animal Center of Anhui Medical University 
(Hefei, China). Animals were kept under 12 h light / 
dark cycles with free access to food and water, and were 
acclimatized for at least 5 days prior to the experiment. 
All animal protocols were approved by the Animal Ethic 
committee of Anhui University of Chinese Medicine 
(Approval No. KJ: 013-16, KJ: 013-18), and experiments 
were conducted in accordance with the NIH “Principles 
of laboratory animal care” guidelines. 
For in vivo pharmacokinetic studies, eighteen 
healthy Sprague-Dawley rats (250 ± 20 g) were randomly 
divided into three groups (n = 6) and fasted 12 h prior to 
the gavage administration of drug formulations. Marketed 
tacrolimus powder, tacrolimus-SDP, and optimized 
tacrolimus-CSP were dispersed in normal saline of 
10 mg/mL. The drugs were administered to rats by gavage 
through a syringe fitted with a flexible oral-zoned catheter 
at a tacrolimus dose of 3 mg/kg. For tacrolimus suspension 
treatment group, blood samples were withdrawn from the 
retro-orbital plexus using heparin sodium-treated syringes 
at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 12 and 24 h after drug 
dosing. For tacrolimus-SDP and tacrolimus-CSP treatment 
groups, blood samples were withdrawn from the retro-
orbital plexus using heparin sodium-treated syringes at 1, 
1.5, 2, 3, 4, 4.5, 5, 6, 8, 10, 12 and 24 h after drug dosing. 
The blood samples were kept below -20 °C until analysis 
by a UPLC assay as described below.
For the tacrolimus biodistribution studies, seventy-
two healthy Sprague-Dawley rats (250 ± 20 g) were 
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randomly divided into three groups (n = 24): tacrolimus 
suspension group, tacrolimus-SDP group, and tacrolimus-
CSP group. Rats were deprived foods in 12 h prior to 
dosing. The drugs were gavaged to rats through a syringe 
fitted with a flexible oral catheter at a tacrolimus dose of 
3 mg/kg. For each group, rats (n = 3) were anesthesia by 
5% chloral hydrate and sacrificed at pre-determined time 
points of 2, 4, 6, 8, 10, 12, 16 and 24 h following drug 
dosing, respectively. The rat tissues (stomach, proximal 
small intestine, distal small intestine, cecum and colon) 
were removed quickly and cautiously. Next, the samples 
were cut into tiny pieces, weighed and homogenized with 
the normal saline using a homogenizer (T18 ULTRA-
TURRAX, IKA Co., Ltd, Germany). After centrifuging 
at 3500 rpm for 15 min at 4 °C, 200 μL of supernatants 
samples were collected and stored at -20 °C until UPLC 
analysis.
Determination of tacrolimus in rat blood and 
tissue samples 
Tacrolimus concentrations in blood and tissue 
samples were determined using a UPLC method. For 
sample preparation, blood or tissue supernatants samples 
(200 μL), NaOH solution (0.2 mol/L, 200 μL) and internal 
standard solution (ascomycin, 200.7 ng/mL, 100 μL) 
were added. The mixed samples were then extracted with 
methyl tert-butyl ether (3 mL), by shaking on a mechanical 
shaker (TYXH-II, Shanghai Green Instrument Co., Ltd, 
China) for 3 min. After centrifugation at 3000 rpm for 3 
min at 4 °C, the upper organic layer was removed and 
evaporated to dryness under nitrogen gas at 50 °C. The 
residue was dissolved in 100 μL of the mobile phase. 
After centrifugation for 12000 rpm for 10 min at 4 °C, 
2 μL of sample supernatant was analyzed by UPLC 
system (ACQUITY UPLC H-Class system, quaternary 
pump, Tunable UV detector, Waters Co., Ltd, USA). 
Chromatography was performed using an ACQUITY 
UPLC BEH C18 column (50 mm × 2.1 mm, 1.7 μm, 
Waters Co., Ltd, USA) at 45 °C, while data analysis 
was performed using the Empower 3 chromatography 
data software (Waters Co., Ltd, USA). The detection 
wavelength of tacrolimus was at 220 nm. The mobile phase 
was a mixture of acetonitrile and 0.1% phosphoric acid 
solution (75:25, v/v) and its flow rate was at 0.3 mL/min. 
Pharmacokinetic analysis
Cmax and its time (Tmax) were directly obtained 
from the mean blood concentration-time curve. Some 
other important pharmacokinetic parameters, e.g. 
biological half-life (t1/2), mean residence time (MRT) and 
area under the curve (AUC), were calculated using DAS 
2.0 pharmacokinetics software. 
In vitro-in vivo correlation
To generate in vitro-in vivo correlation (IVIVC), 
the in vitro cumulative percent of tacrolimus release of 
optimized CSP formulation was compared against the 
extent of in vivo absorption, i.e., cumulative AUC values 
of the same formulation (Vemula, 2015c). 
Statistics analysis
All data are expressed as mean ± standard deviation 
(SD). Statistical analysis was performed by SPSS 17.0 
statistical software using one-way ANOVA test. The 
differences are assumed to be statistically significant at p 
< 0.05 and p < 0.01.
RESULTS AND DISCUSSION
Preparation and optimization of tacrolimus solid 
dispersion pellets 
As a biopharmaceutics classification system (BCS) 
class II drug, the clinical efficacy of tacrolimus was 
limited due to its poor water solubility (5-8 μg/mL), 
which is responsible for its low oral bioavailability (Wang, 
Gan, Zhang, 2011). SD technology has been widely 
used to increase the water solubility of lipophilic drugs. 
Tacrolimus-SD had been successfully developed using 
the solvent evaporation method in previous research 
(Fang et al., 2016). The matrix of tacrolimus-SD was 
HPMC and the weight ratio of HPMC: tacrolimus was 
5:1. The tacrolimus and soluble matrix of HPMC were 
formed into a complex so that tacrolimus lost its original 
crystal structure and presented as an amorphous state in 
the SD. In vitro experiments showed that the dissolution 
of tacrolimus-SD was significantly faster than that of 
single tacrolimus or physical mixtures of tacrolimus/
HPMC (Fang et al., 2016). For BCS class II drugs, the 
maintenance of supersaturation sate facilitates drug 
release from the formulations. Yamashita et al., reported 
that the C=O functional groups and O-H of tacrolimus 
could interact with the functional groups of HPMC, 
which contributed to the maintenance of supersaturation 
state of tacrolimus when it was released from the SD 
(Yamashita et al., 2003). 
Extrusion-spheronization is a kind of economical and 
practical technology with high yields, good repeatability 
and suitable for industrial production. The preparation 
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of wet mass takes a vital influence on pellet formulation. 
The excipients with appropriate plasticity and water 
retention are necessary for wet mass preparation. During 
the extrusion-spheronization process, the impacts of drug-
loading rate and the polymers of excipients, including 
filler, disintegrate agent, on SDP micromeritic properties 
were investigated. Different polymers in each excipient 
category were examined as follows: filler (lactose, starch, 
chitosan, MCC), disintegrate agent (PVP, CMC-Na, 
CMS-Na, L-HPC) and four levels of drug-loading 
rate (5%, 10%, 15%, 20%), to evaluate the quality of 
tacrolimus-SDP. The formulations of tacrolimus-SDP 
with different compositions were given in the Table I and 
their micromeritic property characterization of angle of 
repose, friability, yield and dissolution rate is shown in 
the Table II.
The characterization results of tacrolimus-SDP 
prepared by various filler agents (F1, F2, F3, F4, F5) 
suggested that spherical shape pellets with less rod and 
dumbbell shape were prepared by the formulations of 
F3, F4 and F5. Using lactose alone in F4 caused the 
conglutination of pellets in spheronization process. 
The yields of F3 and F5 both were above 70%, and 
had appropriate degrees of angle of repose, friability. 
Considering the hydrophobicity of MCC, the combination 
of MCC and lactose was applied to improve pellet 
dissolution rather than using MCC alone as the filler 
agent. The weight ratios of lactose and MCC were 
further investigated in 1:1.5, 1:1 and 1.5:1 (F14, F15, 
F16). The appearance of pellets was spherical shape in 
F14 formulation (lactose: MCC=1:1.5); the yield and 
dissolution rate were 76.8% and 83.4%, respectively. The 
results indicated the yield decreased as the proportion of 
lactose increased in the SDP. 
The micromeritic characterization and the 
dissolution studies were applied by tacrolimus-SDP 
with various disintegrate agents (F6, F7, F8, F9). The 
results showed that the F8 with CMS-Na had the highest 
dissolution rate. When water infiltrated into the interior of 
pellet and absorbed by CMS-Na, CMS-Na had powerful 
swelling ability and eventually caused pellet collapse, 
which accelerated disintegration process of SDP. CMS-Na 
is an appropriate disintegrate agent for tacrolimus-
SDP. The proportion of 4% CMS-Na was adopted in 
the formulation. Considering the absorption difference 
based on the individual physiological or pathological 
gastrointestinal tract conditions, if the SDP core of pellet 
was not immediately disintegrated and released drug 
in targeted site in vivo, the drug may excrete from the 
body without sufficient absorption. Therefore, the SDP 
TABLE I - Composition of tacrolimus-SDP 
Tacrolimus 
(g)
Lactose 
(g)
Starch 
(g)
Chitosan 
(g)
MCC 
(g)
CMC-Na 
(g)
CMS-Na 
(g)
L-HPC
(g)
PVP K30 
(g)
F1 0.8 2.8 3.84 - - 0.32 - - -
F2 0.8 2.8 - 3.84 - 0.32 - - -
F3 0.8 2.8 - - 3.84 0.32 - - -
F4 0.8 6.64 - - - 0.32 - - -
F5 0.8 - - - - 0.32 - - -
F6 0.8 2.8 - - 3.84 - - - 0.32
F7 0.8 2.8 - - 3.84 0.32 - - -
F8 0.8 2.8 - - 3.84 - 0.32 - -
F9 0.8 2.8 - - 3.84 - - 0.32 -
F10 0.4 3.2 - - 3.84 - 0.32 - -
F11 0.8 2.8 - - 3.84 - 0.32 - -
F12 1.2 2.4 - - 3.84 - 0.32 - -
F13 1.6 2.0 - - 3.84 - 0.32 - -
F14 0.8 2.66 3.98 - - - 0.32 - -
F15 0.8 3.32 3.32 - - - 0.32 - -
F16 0.8 3.98 2.66 - - - 0.32 - -
Note: the symbol of “-” expresses data not available. CMC-Na: carboxymethyl cellulose sodium; CMS-Na: carboxymethyl starch 
sodium; L-HPC: low-substituted hydroxypropyl cellulose; MCC: microcrystalline cellulose; PVP: poly vinyl pyrrolidone.
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formulation studies not only met the requirements of next 
process of fluid bed coating, but also needed to consider 
making drug release quickly and completely. The use of 
lactose and MCC as a filler can form sphere SDP with 
uniform size and appropriate friability through extrusion-
spheronization. The addition of super disintegrant of 
CMS-Na ensured the rapid tacrolimus release in targeted 
site. 
The characterization results of different tacrolimus-
loading rate of 5%, 10%, 15%, 20% (F10, F11, F12, F13) 
are shown in the Table II. When the drug-loading rates 
were 15% and 20%, the wet masses were hard and difficult 
to be sieved to small pieces in extrusion process. However, 
when the drug-loading rate decreased to 10%, the quality 
of wet mass was significantly improved and smoothly 
passed through the sieve mesh on extruder. The SDP with 
low drug-loading rate was easily prepared but this may 
increase the oral dose. Therefore, tacrolimus-loading rate 
was determined to be 10%. 
The PVP K30 was chosen as the binder agent using 
30% ethanol solution as solvent. The proportion of the 
binder agent directly affected the viscosity of wet mass 
and pellet preparation. The optimal proportion of PVP K30 
in formulation was determined by practical operation 
because the characteristics of binder agent were directly 
affected by the temperature and humidity in production 
environment. Silica gel was selected as glidant. Adhesion 
of lipophilic drug on the surface of silica gel contributed 
to accelerate the dissolution process. Talc flatted the 
cavity on the surface of pellets, which reduced the friction 
among the pellets in spheronization process. By the 
above screening tests of excipients, the composition and 
quantities of tacrolimus-SDP are listed in the Table III. It 
is worth noting that, as an intermediate of the formulation, 
tacrolimus-SDP showed a pretty high bioavailability 
compared to tacrolimus solution, which was demonstrated 
in subsequent pharmacokinetic experiment.
Preparation and in vitro release kinetic studies of 
tacrolimus colon-specific pellets
To perform film coating of tacrolimus-CSP, the 
tacrolimus-SDP was coated with mixed dispersion of 
Eudragit NE30D, Eudragit L30D55 and talc as time-
dependent layer with specific weight gain in a mini lab-use 
fluidized bed coater. The weight gain was calculated as 
(final weight–original weight) / original weight × 100%. 
Next, the time-dependent layer coated pellets were further 
wrapped on the mixed dispersion of Eudragit L30D55, 
talc and triethyl citrate as pH-dependent layer. Eudragit 
TABLE II - Micromeritic properties and dissolution rate of tacrolimus-SDP
Morphology Angle of repose 
(φ)
Friability 
(F)
Yield 
(Y%)
Dissolution rate 
(%)
F1 Rod and dumbbell shape 19.2 1.38 48.8 -
F2 Rod and dumbbell shape 21.7 1.46 41.9 -
F3 Spherical pellet, less rod and dumbbell shape 15.8 0.72 71.1 -
F4 Spherical pellet but conglutination in 
spheronization process
18.5 0.96 67.5 -
F5 Spherical pellet, less rod and dumbbell shape 16.3 0.81 70.1 -
F6 Spherical pellet 17.3 - 69.8 66.8
F7 Spherical pellet 16.4 - 72.3 72.4
F8 Spherical pellet 16.9 - 70.6 85.2
F9 Spherical pellet 17.8 - 68.5 71.1
F10 Spherical pellet 15.4 0.65 74.6 -
F11 Spherical pellet 15.6 0.69 71.2 -
F12 Hardness and unable to spheronization 18.7 1.12 65.3 -
F13 Hardness and unable to spheronization 21.3 1.41 47.6 -
F14 Spherical pellet 15.1 - 76.8 83.4
F15 Rod and dumbbell shape, hard wet mass 16.2 - 73.1 85.8
F16 Rod and dumbbell shape, hard wet mass 17.6 - 67.5 86.9
Note: the symbol of “-” expresses data not available.
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NE30D is an acrylic coating material, with sustained 
released activity =and swelling in water (Liu et al., 2013). 
Eudragit L30D55 is an anionic enteric-coating material, 
containing -COOH as a functional group and is selectively 
dissolved at pH > 5.5 solutions (He, Li, Tang, 2011). Talc 
is an anti-coherent agent to avoid the aggregation of pellets 
in the fluidized bed. The time-dependent layer consists of 
Eudragit NE30D and Eudragit L30D55. It is reported that 
the mixed Eudragit NE30D and Eudragit L30D55 coating 
can achieve controlled release of the drug and also help 
reduce the time-dependent layer deformation in the storage 
of the formulations (Wulff, Leopold, 2014). 
The time-dependent coated pellets were prepared 
by different weight ratios of 2:1, 4:1, 8:1, 14:1, 16:1 
(Eudragit NE30D: Eudragit L30D55) with a constant 
weight gain of 10%. Figure 1A shows their in vitro release 
in the sequential media of pH 1.2 HCl (0.1 mol/L), pH 6.8 
and pH 7.2 PBS for 2 h, 3 h and the remaining 7 h. The 
cumulative release of coated pellets by different ratios of 
2:1, 4:1, 8:1, 14:1, 16:1 was 48.36%, 37.98%, 31.46%, 
23.94% and 20.11% in 0-5 h, respectively. At the same 
time point, the pellet with lower proportion of Eudragit 
NE30D had a higher cumulative release level. The CSP 
should be stable in acid medium; almost no drug released 
in the pH 6.8 PBS and released most drugs in the pH 7.4 
PBS. The pellets with the ratios of 14:1 and 16:1 had less 
cumulative releasein pH 6.8 PBS in 0-5 h, however, they 
did not release drug completely at 12 h. Therefore, the ratio 
of 8:1 (Eudragit NE30D: Eudragit L30D55) was selected 
for further studies. 
A series of coated pellets were prepared by different 
thicknesses of time-dependent layer and quantified by the 
total weight gain (5%, 10%, 15%, 20%, 25%) difference 
with a constant Eudragit L30D55 to Eudragit NE30D 
ratio of 8:1. Figure 1B shows their cumulative release. 
The cumulative release of coated pellets was inversely 
proportional to the thicknesses of time-dependent layer. 
The cumulative release of 5% and 10% weight gain was 
40.36% and 31.46% in 0-5 h., respectively. Tacrolimus 
was metabolized by cytochrome P450 3A in liver and 
intestine. CYP3A displayed significant interindividual 
and intraindividual variability (Hebert, 1997). Therefore, 
tacrolimus rapid release in a short time period may cause 
potential toxicological risk to liver and intestine due to 
its narrow therapeutic index. The cumulative release of 
23.94% and 20.11% was obtained by the weight gain 
of 20% and 25% in 0-5 h, respectively; however, the 
drugs were not released completely in the time period 
of 0-12 h. Therefore, 15% weight gain was selected for 
time-dependent layer.
To achieve colon target release profile, the 
pH-dependent layer of Eudragit L30D55 was wrapped 
on the surface of time-dependent layer as an enteric 
coating. The formulation of interior time-dependent layer 
was constant according to the optimization. The 10% of 
triethyl citrate was used as plasticizer for Eudragit L30D55 
in pH-dependent layer coating (Wagner et al., 2000). 
Figure 1C shows the release profiles of the coated pellets 
with various weight gains (5%, 10%, 15%, 20%, 25%) 
of the pH-dependent layer in gradient pH solutions of 
TABLE III - Composition of optimized tacrolimus-SDP
Ingredients Quantities (%) Functions
Tacrolimus solid 
dispersion 
10 Active drug
Lactose and MCC 
(1:1.5, w:w)
83 Filler
CMS-Na 4 Disintegrate
Silica gel and talc 3 Lubricant and 
glidant
PVP K30 According to the 
practical operation
Binder
Note: MCC: microcrystalline cellulose; CMS-Na: carboxymethyl 
starch sodium; PVP: poly vinyl pyrrolidone.
FIGURE 1 - The cumulative release of colon-specific pellets with (A) different ratios of Eudragit NE30D: Eudragit L30D55, (B) 
different weight gains of time-dependent layer, (C) different weight gains of pH-dependent layer. Data are presented as mean ± SD 
(n = 3).
Solid dispersion-based pellet for colon delivery of tacrolimus through time- and pH-dependent layer coating: preparation, in vitro and in vivo studies
Braz. J. Pharm. Sci. 2019;55:e17309 Page 9 / 14
pH 1.2, pH 6.8 and pH 7.2 for 2 h, 3 h, and 7 h. Tacrolimus 
hardly released in the pH 1.2 HCl solution when the 
coating weight gain was greater than 5%. In pH 6.8 PBS, 
the pH-dependent layer of Eudragit L30D55 dissolved 
and exposed the internal time-dependent coated layer. 
Therefore, the initial release rate in the pH 6.8 PBS was 
determined by the thickness of pH-dependent layer. Taking 
into account the release rate of inner time-dependent layer, 
the pH-dependent layer of Eudragit L30D55 should not 
be too thick to release the inside drug. Therefore, 10% of 
weight gain was chosen as pH-dependent layer. 
Three batches of tacrolimus-CSP (B1, B2, B3) 
were prepared according to the final optimized time- and 
pH-dependent layer formulations. The appearance of 
optimized tacrolimus-CSP is shown in Figure 2. Figure 3 
shows thier in vitro cumulative release. The release curve 
showed that tacrolimus was hardly detected in pH 1.2 
HCl solution in initial 2 h. This suggested that pH-
dependent layer could protect CSP from disintegration 
in the gastric acid. In pH 6.8 PBS, the pH-dependent 
layer was gradually dissolved and the interior time-
dependent layer performed a sustained-release function. 
Therefore, tacrolimus released from CSP slowly at 2-5 h. 
Furthermore, tacrolimus-CSP performed a quick and 
complete drug release in the pH 7.2 stimulated colonic 
juice. The cumulative release profiles showed that curve 
raised sharply after 5 h and still had a release trend 
after 12 h. This mainly owed to the super disintegrating 
agent of CMS-Na and time-dependent coating of 
Eudragit NE30D in CSP. The encapsulation efficiency 
of tacrolimus-CSP was 89.88% and the drug-loading 
rate was 1.499%. 
According to the fit curve results of tacrolimu-CSP 
dissolution, it appeared that the Weibull model was the 
most appropriate to its in vitro release. The correlation 
coefficient (R2) and model selection criterion (MSC) 
were 0.9908 and 3.3996, respectively. When comparing 
different models, the most appropriate model appeared 
the largest MSC. Generally, the value of MSC higher than 
two to three suggested a good fit (Mayer et al., 1999). The 
values of initial parameter (α, β, Ti) of Weibull equation 
were calculated and given in Table IV. The n value 
of Koresmeyer–Peppas model was 1.243, indicating 
tacrolimus release from the CSP consistent with supercase-
II transport in the mechanism of matrix dissolution. The 
MDT value of optimized tacrolimus-CSP was found to be 
5.98. The result indicated that tacrolimus mainly released 
in the pH 7.2 stimulated colonic juice, which agreed with 
the in vivo sustained-release profile of MRT. Time in hours 
to take 10% and 80% drug release can predict the ability 
of colon-specific release from CSP. The T10% and T80% 
values of optimized CSP were found to be 3.149 h and 
10.655 h respectively. From these parameters, tacrolimus-
CSP prospectively showed 2-3 h lag time, which provided 
most or complete drug release in colon. All these results 
are given in Table IV. Furthermore, from the cumulative 
release curve in Figure 3, the release behavior of CSP was 
significantly different with SD and SDP. The value of f2 
between dissolution profiles of CSP and SDP was found 
to be 13.54.
FIGURE 2 - Appearance of tacrolimus-CSP of optimized formulation. Batch numbers: (A) B1, (B) B2, (C) B3. 
FIGURE 3 - The cumulative release of tacrolimus-SD, 
tacrolimus-SDP and tacrolimus-CSP of optimized formulations. 
Data are presented as mean ± SD (n = 3). Batch numbers of 
tacrolimus-CSP: () B1, () B2, () B3.
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In vivo pharmacokinetics studies 
The representative UPLC chromatograms of 
blank blood sample, blank blood sample spiked with 
tacrolimus and ascomycin, the blood sample after oral 
administration of tacrolimus-CSP are shown in Figure 
4. The chromatograms showed a stable base line, good 
resolution between tacrolimus and ascomycin and no 
other endogenous interference at the retention time 
of tacrolimus. The concentration of tacrolimus was 
determined by standard calibration curve in a range of 
20.37-1001.8 ng/mL with a reference substance. The 
regression equation was A = 3.016 × 10-4C - 2.831 × 10-4 
(r = 0.9992). The mean absolute recovery and the mean 
relative recovery were 71.31 ± 4.47% and 94.84 ± 1.44%, 
respectively. The lower detection limit of this method was 
20 ng/mL. The RSD for intra-day and inter-day precision 
were 5.85% and 2.92%, respectively, indicating good 
reproducibility. In summary, this internal standard method 
demonstrated acceptable accuracy, precision, and linearity, 
and was used to determine tacrolimus concentration in rat 
blood. 
To investigate the absorption enhancement of 
tacrolimus-SDP and tacrolimus-CSP, a total of of 18 rats 
were chosen for the pharmacokinetic experiment with the 
tacrolimus suspension as a control. The blood tacrolimus 
FIGURE 4 - UPLC chromatograms of (A) blank blood sample, (B) blank blood sample spiked with tacrolimus and ascomycin, (C) 
the blood sample after oral administration of tacrolimus-CSP. 1: ascomycin; 2: tacrolimus.
TABLE IV - Release kinetics of optimized tacrolimus-CSP
Weibull equation
n MDT T10% T80%
α β Ti MSC R2
Tacrolimus-CSP 5.714 1.082 3.141 3.3996 0.9908 1.243 5.98 3.149 10.655
Note: MDT: mean dissolution time; MSC: model selection criterion; n: diffusional exponent; R2: correlation coefficient; T10%: time 
to release 10% drug; T80%: time to release 80% drug; Ti: the location parameter which represents the lag time before the onset of 
the dissolution or release process; α: the scale parameter which defines the time scale of the process; β: the shape parameter which 
characterizes the curve, S-shaped with upward curvature followed by a turning point (β > 1), or parabolic with a higher initial slope 
and after that consistent with the exponential (β < 1) (Zhang et al., 2010).
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concentration-time curves are shown in Figure 5. The 
blood tacrolimus concentration from tacrolimus-SDP 
group was obviously higher than tacrolimus suspension 
group. The reason was that the SD technology increased 
the solubility of tacrolimus and enhanced its absorption 
in intestine part. Tacrolimus was not detected in first 1 h 
after administration of the tacrolimus-CSP group. After 
4.5 h, the blood concentration of the tacrolimus-CSP 
group began to gradually drop and maintained a steady 
state for a long time. The time to achieve maximum blood 
concentration of the CSP group was longer than other two 
groups. This implied that CSP had a less drug release in 
stomach and upper small intestine. The MRT(0-∞) value of 
tacrolimus-CSP group was 1.87-fold longer than that of 
the tacrolimus-SDP group (15.57 ± 3.04 vs. 8.32 ± 5.96), 
suggesting CSP had a good ability to maintain a stable 
blood concentration state and a potential developed into 
sustained-release formulations. 
Some important pharmacokinetic parameters were 
calculated using DAS 2.0 pharmacokinetics software 
and are shown in Table V. The best compartment 
models of the three groups in rats were both two-
compartment models with a weight coefficient of 
1.  The AUC (0-∞) and Cmax value of tacrolimus-
CSP were 1.99-fold and 4.39-fold higher than that 
obtained after administration of tacrolimus suspension 
(1568.16 ± 214.97 vs. 1090.23 ± 125.53 ng·h/mL), 
(195.68 ± 3.14 vs. 147.51 ± 5.34 ng/mL), respectively, 
which clearly confirmed the role of CSP in enhancing 
the bioavailability of tacrolimus. The underlying reason 
was that tacrolimus co-precipitating with HPMC, a 
hydrophilic excipient, formed an amorphous state in 
the pellets, which increased the solubility of tacrolimus 
in the colon juice. In addition, CMS-Na facilitated 
water penetration into the pellet core which led to a 
faster drug release. Given the BCS class II drug of 
tacrolimus, the dissolution rate was the rate-limiting 
step for its in vivo absorption (Wang, Gan, Zhang, 
2011). Therefore, the tacrolimus in CSP was more 
easily absorbed compared to tacrolimus suspension 
through oral administration. However, the AUC(0-∞) and 
Cmax values of tacrolimus-CSP group were lower than 
that obtained by administration of the tacrolimus-SDP 
group (1568.16 ± 214.97 vs. 2479.58 ± 183.33 ng·h/mL, 
195.68 ± 3.14 vs. 646.16 ± 8.15 ng/mL). It suggested that 
the drug concentration absorbed into the blood circulation 
was less than that in the colon tissue, which was conducive 
to the increase of drug concentration in colon. Prolonged 
MRT, reduced Cmax and trending toward a delayed Tmax 
were observed for CSP. These results clearly indicated 
that the controllable release of tacrolimus from CSP 
successfully resulted in the targeted absorption in vivo.
FIGURE 5 - Blood concentration–time curves of tacrolimus in 
rats. :The blood tacrolimus concentration from tacrolimus 
suspension group. : The blood tacrolimus concentration from 
tacrolimus-SDP group. : The blood tacrolimus concentration 
from tacrolimus-CSP group. Data are presented as mean ± SD 
(n = 6).
TABLE V - Pharmacokinetic parameters of tacrolimus suspension, tacrolimus-SDP, tacrolimus-CSP groups after oral administration 
to rats
Parameter Tacrolimus suspension Tacrolimus-SDP Tacrolimus-CSP
t1/2α(h) 1.23±0.02 2.07±0.55 23.42 ±0.81*
t1/2β(h) 11.69±1.65 27.63±2.04 69.31±4.91*
Tmax (h) 0.75±0.02 0.5±0.03 4.5±0.24**
Cmax (ng/mL) 147.51±5.34 646.16±8.15 195.68±3.14**
AUC(0-∞) (ng·h/mL) 1090.23±125.53 2479.58±183.33 1568.16±214.97*
MRT(0-∞) (h) 5.14±3.24 8.32±5.96 15.57±3.04*
Note: Data are presented as mean ± SD (n = 6). t1/2: biological half-life; Cmax: maximum blood concentration; Tmax: peak time; 
AUC: area under the curve; MRT: mean residence time. *p < 0.05 vs. tacrolimus suspension group; **p < 0.01 vs. tacrolimus 
suspension group
J. Guo, H. Fang, S.. Gui, Y. Huang
Braz. J. Pharm. Sci. 2019;55:e17309Page 12 / 14
In vitro-in vivo correlation
IVIVC was carried out for optimized tacrolimus-
CSP by plotting the in vitro cumulative percentage of 
tacrolimus release on X-axis and the cumulative AUC 
obtained after oral administration on Y-axis. From the 
Figure 6, the least square regressions yielded an essentially 
linear pattern (R2 > 0.95), indicating a good correlation 
between the in vitro cumulative percentage of drug release 
and in vivo drug absorption.
In vivo biodistribution studies 
Figure 7 shows the biodistribution of tacrolimus 
after oral administration of suspensions, SDP and CSP 
examined based on μg tacrolimus per g tissue. At 2-6 h 
after oral administration of tacrolimus-suspensions and 
tacrolimus–SDP, a fast and wide distribution of drug was 
observed in stomach, proximal and distal small intestine, 
cecum and colon. However, tacrolimus derived from CSP 
was nearly no drug detected in the stomach and proximal 
small intestine, which indicated a control-release effect 
in gastrointestinal tract. Tacrolimus derived from CSP 
was mostly accumulated in cecum and colon at 6-24 h. 
Twelve hours after oral administration, tacrolimus 
showed a remarkable selective distribution in colon, 
about 1.57-fold to cecum and 35-fold to distal small 
intestine. Yura et al. (1999) evaluated the distribution of 
radioactive [3H]-labelled tacrolimus solution in rat by 
intravenous administration. They confirmed that 64% 
dose of [3H]-tacrolimus was accumulated in the small 
intestine after 8 h following injection (Yura et al., 1999). 
Once in bloodstream, tacrolimus was inclined to distribute 
into fatty organs like liver and small intestine due to its 
highly lipophilic nature. Therefore, tacrolimus loaded 
by colon-specific delivery system and selectivity release 
drug in the colon part might be favorable for therapeutic 
efficacy enhancement for colitis. Furthermore, in the 
end of time period, tacrolimus concentration from CSP 
group was higher than the tacrolimus-suspension and 
tacrolimus–SDP group, suggesting that the absorption and 
elimination of drug derived from CSP maybe occurat the 
same time in colon. However, in other two groups, there 
were only elimination processes in the end of time period. 
These results proved that the combination of OCDDS and 
SD technology successfully improved the solubility of 
tacrolimus in the colon juice and facilitated the absorption 
for oral administration. In general, the order of tacrolimus 
accumulation in the colon was as follows: CSP > SDP > 
suspensions. 
It is worth noting that toxicity of tacrolimus is dose 
dependent, and this was confirmed in a retrospective 
study of patients with severe steroid-refractory or steroid-
dependent inflammatory bowel disease treated with low 
dose tacrolimus. This research indicated that lower target 
serum concentration levels of tacrolimus may reduce the 
incidence of adverse events (Baumgart et al., 2006). Colon 
targeted tacrolimus-CSP may reduce the potential systemic 
toxicity of immunosuppressant, such as tremor, headache, 
diarrhea, hypertension and nausea, compared to clinical 
used tacrolimus capsules or injections (Baumgart et al., 
2008). A further consideration of tacrolimus-CSP should 
FIGURE 6 - In vitro-in vivo correlation plot of optimized 
tacrolimus-CSP.
FIGURE 7 - Tacrolimus concentrations in different tissues after oral administration of (A) tacrolimus suspension, (B) tacrolimus-
SDP, (C) tacrolimus-CSP. Data are presented as mean ± SD (n = 3).
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be given to the increased risk of intestinal side reaction and 
enterotoxicity due to the rapid release effect of SD in colon
CONCLUSION 
A novel OCDDS with SD technology was successfully 
developed in this study. Tacrolimus-CSP was prepared by 
tacrolimus-SDP using extrusion-spheronization and coated 
with pH-dependent layer (Eudragit L30D55) and time-
dependent layer (Eudragit L30D55 and Eudragit NE30D). 
Based on in vitro drug release studies, optimized tacrolimus-
CSP showed a significant drug release level in the pH 7.4 
PBS. The drug release from optimized tacrolimus-CSP 
followed Weibull model and the drug release mechanism 
followed supercase-II transport. In vivo pharmacokinetic 
and biodistribution studies indicated that the tacrolimus-CSP 
negligibly released the drug in stomach and small intestine, 
but specifically delivered the drug to colon and showed a 
slow and sustained drug absorption compared to tacrolimus-
SDP and tacrolimus suspensions. From the IVIVC results, 
there was a good correlation between the in vitro and in 
vivo parameters. The local immunosuppression effects of 
tacrolimus may decrease unwanted gastrointestinal irritation 
and systemic toxicity compared to conventional injection 
administration. In conclusion, it seems that the combined 
SD pellets with both pH-sensitive and time-dependent 
coating methods would be a promising approach for colon 
targeted delivery of tacrolimus.
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